Wire · opportunities
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
The FDA approved talazoparib in combination with enzalutamide for the treatment of metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations, based on phase 3 TALAPRO-3 trial results showing a significant radiographic progression-free survival benefit.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You have an early treatment option for prostate cancer tied to genetic testing. Molecular reports now gatekeep access, so your clinical and pharmacy teams must align tightly on testing and patient eligibility.
◆ Coverage
3 sources · 26 Oct 2026
◆ Related on Wire
◆ Topics